|
Table 1
Summary of 25 randomized clinical studies and tvo
drug-monitoring studies on the efficiency of Hypericum
in the treatment of depression and anxiety.
| Authors year |
No of cases |
Total hypericin/day |
Weeks |
Target Parameters |
Test preparation |
Respons rate |
Compared treatment |
Resp. rate |
Rating |
| | |
| | | |
| | |
| Witte, 1995 | 97
| 0,5 mg x 2 | 6
| HAMD, D-S | Psychotonin
| 79 % | Placebo
| 56% | -
|
| Ditzler, 1994 | 60
| 0,24 mg x 2 | 8
| D-S | Neurapas***
| 67% | Placebo
| 33% | -
|
| Albrecht, 1994 | 1060
| 0,3 mg x 3 | 4
| HAMD, D-S | Jarsin
| 75% | None
| - | -
|
| Woelk, 1993 | 3250
| 0,9 mg x 3 | 4
| D-S | Jarsin 300
| 82% | None
| - | -
|
| Sommer,1993 | 105
| 0,9 mg x 3 | 4
| HAMD | Jarsin 300
| 67% | Placebo
| 28% | 41
|
| Huebner,1993 | 40
| 0,9 mg x 3 | 4
| HAMD, B-L,CGI | Jarsin 300
| 70% | Placebo
| 47% | 54
|
| Hänsgen, 1993 |
100 | 0,9 mg x 3
| 6 | HAMD, D-S, CGI, BEB
| Jarsin 300 | 81%
| Placebo | 26%
| 55 |
| Vorbach, 1993 | 135
| 0,9 mg x 3 | 6
| HAMD, D-S, CGI | Jarsin 300
| 82% | Imipramin
| 62% | 74
|
| Harrer, 1993 | 102
| 1 mg x 3 | 4
| HAMD, D-S, CGI | Jarsin 300
| 61% | Maprotilin,
| 67% | 70
|
| Bergmann, 1993 | 76
| 0,25mg x3 | 6
| HAMD, Bf-S | Esbericum
| 84% | Amitryptilin
| 74% | 38
|
| Martinez, 1993 | 20
| 0,9 mg x 3 | 4
| HAMD, (SAD-patients) |
Jarsin + 300 Lux | 60%
| Jarsin + 3000Lux | 72%
| 38 |
| König, 1993 | 112
| 0,5-1mg x 2 | 6
| Bf-S | Extract Z 90017
| 53% | Placebo
| 53% | -
|
| Lehrl, 1993 | 50
| 0,37 mg x 3 | 4
| HAMD, KAI | Jarsin
| 42% | Placebo
| 25% | 25
|
| Schmidt, 1993 | 65
| 0,37 mg x 3 | 6
| HAMD, Cognition | Jarsin
| 67% | Placebo
| 26.7% | -
|
| Quandt, 1993 | 88
| 0,37 mg x 3 | 4
| HAMD | Psychotonin M
| 70,7% | Placebo
| 7,7% | 49
|
| Reh, 1992 | 50
| 0,5mg x 2 | 8
| HAMD | Neuroplant
| 70% | Placebo
| 45% | 55
|
| Osterheider, 1992 | 46
| 0,25mg x 2 | 8
| HAMD | Neuroplant
| 0% | Placebo
| 0% | 25
|
| Harrer, 1991 | 116
| 0.37 mg x 3 | 6
| HAMD, HAMA, D-S | Psychotonin
| 75% | Placebo
| 25% | 52
|
| Halama, 1991 | 50
| 0.3 mg x 3 | 4
| HAMD, B-L, CGI | Jarsin
| 60% | Placebo
| 12% | 55
|
| Werth, 1989 | 30
| 0,37 mg x 3 | 3,5
| HAMDafter amputation |
Psychotonin M | 73%
| Imipramin | 60%
| 43 |
| Schmidt, 1989 | 40
| 0,37 mg x 3 | 4
| HAMD , STAI | Psychotonin M
| 65% | Placebo
| 33% | -
|
| Kniebel, 1988 | 130
| 0,1 mg x 2* | 6
| HAMD, CGI, Bf-S | Sedariston
| 88% | Amitryptilin
| 80% | 35
|
| Schilch, 1987 | 49
| 0,25 mg x 3 | 4
| HAMD | Psychotonin M
| 28.4% | Placebo
| -23% | 45
|
| Warnecke, 1986 | 60
| 0,3mg x 2 | 12
| HAMA, SDS, CGI | Hyperforat
| 77%** | Diazepam
| 50% | -
|
| Steger, 1985 | 93
| 0,1 mg x 2 * | 6
| CGI, D-S, B-L | Sedariston
| 70% | Desipramin
| 30% | -
|
| Panijel, 1985 | 100
| 0,1 mg x 2* | 2
| CGI, B-L, STAI | Sedariston
| 78%** | Diazepam
| 54% | -
|
| Hoffmann, 1979 | 60
| 3 mg x 3 | 6
| Own Scale | Hyperforat
| 61.4% | Placebo
| 15.2% | 16
|
D-S = Depression Scale according to von Zerssen;
CGI = Clinical Global Impression score; B-L = von Zerssen Health
Compliant survey; BEB = Hänsgens complaint inventory; Bf-S
= v. Zerssen´s SelfRating Scale; STAI = State Trait Anxiety
Inventory ; KAI = Lehrl's Short Test on General Information processing;
SAD = Seasonal Affective Disorders, SDS =Self Rating Depression
Scale * = + 50 mg Valeriana in combination-medication. ** Measured
by CGI *** combination medication with Hypericum,
Valeria, Passiflorae, Coridalis cavae and Eschscholixiae californiae
Click Here for Index of Charts & Tables
|
